PCLAF and Kaposi's sarcoma: Spiro-flavostilbenoids 36–38 inhibited Kaposi sarcoma (KS) cell proliferation, migration, and synthesis of the inflammatory mediator PAF (platelet-activating factor) in vitro [122].